Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Leslie ChoAndrew M KaunitzStephanie S FaubionSharonne N HayesEmily S LauNicole PristeraNandita ScottJan L ShifrenChrisandra L ShufeltCynthia A StuenkelKathryn J Lindleynull nullPublished in: Circulation (2023)
Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women's health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.
Keyphrases
- cardiovascular disease
- healthcare
- end stage renal disease
- public health
- polycystic ovary syndrome
- newly diagnosed
- ejection fraction
- type diabetes
- chronic kidney disease
- mental health
- pregnant women
- coronary artery disease
- cardiac surgery
- risk assessment
- stem cells
- mesenchymal stem cells
- acute kidney injury
- pregnancy outcomes
- cardiovascular risk factors
- depressive symptoms
- estrogen receptor
- cervical cancer screening